InBody Co.,Ltd Logo

InBody Co.,Ltd

041830.KQ

(0.0)
Stock Price

23.400,00 KRW

12.63% ROA

15.58% ROE

11.51x PER

Market Cap.

374.522.368.750,00 KRW

0% DER

1.04% Yield

21.56% NPM

InBody Co.,Ltd Stock Analysis

InBody Co.,Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

InBody Co.,Ltd Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

InBody Co.,Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

InBody Co.,Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

InBody Co.,Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

InBody Co.,Ltd Revenue
Year Revenue Growth
2012 33.230.296.360
2013 36.786.609.020 9.67%
2014 48.940.140.490 24.83%
2015 68.949.097.530 29.02%
2016 79.848.382.290 13.65%
2017 93.253.712.990 14.38%
2018 99.635.442.560 6.41%
2019 117.058.914.070 14.88%
2020 107.122.053.680 -9.28%
2021 137.836.961.980 22.28%
2022 160.003.774.080 13.85%
2023 162.641.406.400 1.62%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

InBody Co.,Ltd Research and Development Expenses
Year Research and Development Expenses Growth
2012 2.289.212.000
2013 2.710.807.000 15.55%
2014 3.392.417.000 20.09%
2015 4.882.220.000 30.51%
2016 5.376.619.000 9.2%
2017 7.250.497.000 25.84%
2018 5.210.831.000 -39.14%
2019 5.242.765.000 0.61%
2020 5.800.563.000 9.62%
2021 8.061.689.000 28.05%
2022 8.778.754.000 8.17%
2023 8.419.760.000 -4.26%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

InBody Co.,Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 306.033.000
2013 238.505.000 -28.31%
2014 381.384.000 37.46%
2015 388.854.000 1.92%
2016 507.228.000 23.34%
2017 580.536.000 12.63%
2018 557.027.000 -4.22%
2019 562.904.000 1.04%
2020 500.655.000 -12.43%
2021 503.788.000 0.62%
2022 655.836.000 23.18%
2023 794.856.000 17.49%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

InBody Co.,Ltd EBITDA
Year EBITDA Growth
2012 5.575.729.970
2013 7.401.870.390 24.67%
2014 11.203.785.610 33.93%
2015 21.376.543.250 47.59%
2016 23.788.949.780 10.14%
2017 26.650.846.290 10.74%
2018 25.693.479.670 -3.73%
2019 31.625.421.960 18.76%
2020 23.519.082.180 -34.47%
2021 40.287.426.980 41.62%
2022 46.078.052.760 12.57%
2023 40.528.693.760 -13.69%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

InBody Co.,Ltd Gross Profit
Year Gross Profit Growth
2012 23.605.964.200
2013 25.874.038.640 8.77%
2014 34.166.444.060 24.27%
2015 49.052.030.120 30.35%
2016 57.372.103.630 14.5%
2017 68.836.027.340 16.65%
2018 72.178.389.510 4.63%
2019 85.702.596.080 15.78%
2020 77.058.463.610 -11.22%
2021 100.917.903.760 23.64%
2022 120.591.466.700 16.31%
2023 125.164.187.360 3.65%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

InBody Co.,Ltd Net Profit
Year Net Profit Growth
2012 5.642.751.340
2013 6.194.379.890 8.91%
2014 8.879.319.650 30.24%
2015 17.310.909.040 48.71%
2016 16.986.910.209 -1.91%
2017 19.321.817.230 12.08%
2018 19.670.671.140 1.77%
2019 20.428.475.050 3.71%
2020 17.517.981.060 -16.61%
2021 34.033.493.240 48.53%
2022 33.815.534.939 -0.64%
2023 28.181.457.280 -19.99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

InBody Co.,Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 415
2013 455 8.79%
2014 652 30.21%
2015 1.272 48.74%
2016 1.248 -1.92%
2017 1.430 12.73%
2018 1.459 1.92%
2019 1.532 4.77%
2020 1.335 -14.68%
2021 2.613 48.89%
2022 2.596 -0.66%
2023 2.163 -19.97%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

InBody Co.,Ltd Free Cashflow
Year Free Cashflow Growth
2012 3.543.282.430
2013 3.657.640.440 3.13%
2014 8.792.349.700 58.4%
2015 3.863.255.690 -127.59%
2016 10.607.244.950 63.58%
2017 13.263.845.010 20.03%
2018 -23.159.053.250 157.27%
2019 21.130.273.280 209.6%
2020 26.813.986.670 21.2%
2021 18.903.370.790 -41.85%
2022 25.039.112.320 24.5%
2023 9.337.038.950 -168.17%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

InBody Co.,Ltd Operating Cashflow
Year Operating Cashflow Growth
2012 4.355.328.120
2013 6.994.673.360 37.73%
2014 10.259.230.790 31.82%
2015 11.178.514.970 8.22%
2016 18.238.319.930 38.71%
2017 18.576.147.010 1.82%
2018 17.704.892.100 -4.92%
2019 24.206.000.620 26.86%
2020 28.500.349.900 15.07%
2021 30.350.938.960 6.1%
2022 30.418.862.590 0.22%
2023 11.073.886.430 -174.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

InBody Co.,Ltd Capital Expenditure
Year Capital Expenditure Growth
2012 812.045.690
2013 3.337.032.920 75.67%
2014 1.466.881.090 -127.49%
2015 7.315.259.280 79.95%
2016 7.631.074.980 4.14%
2017 5.312.302.000 -43.65%
2018 40.863.945.350 87%
2019 3.075.727.340 -1228.59%
2020 1.686.363.230 -82.39%
2021 11.447.568.170 85.27%
2022 5.379.750.270 -112.79%
2023 1.736.847.480 -209.74%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

InBody Co.,Ltd Equity
Year Equity Growth
2012 46.134.394.300
2013 51.558.488.020 10.52%
2014 59.610.449.950 13.51%
2015 76.349.656.830 21.92%
2016 92.332.630.560 17.31%
2017 106.516.223.450 13.32%
2018 124.532.453.300 14.47%
2019 139.830.175.110 10.94%
2020 150.182.330.500 6.89%
2021 183.782.288.340 18.28%
2022 216.039.393.699 14.93%
2023 230.506.659.540 6.28%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

InBody Co.,Ltd Assets
Year Assets Growth
2012 48.162.809.780
2013 53.672.981.910 10.27%
2014 63.171.082.010 15.04%
2015 82.459.250.480 23.39%
2016 97.059.397.400 15.04%
2017 112.024.745.210 13.36%
2018 131.686.125.520 14.93%
2019 154.903.555.780 14.99%
2020 166.150.336.180 6.77%
2021 203.760.043.200 18.46%
2022 242.665.327.370 16.03%
2023 258.836.010.290 6.25%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

InBody Co.,Ltd Liabilities
Year Liabilities Growth
2012 2.028.415.480
2013 1.918.484.690 -5.73%
2014 3.394.163.510 43.48%
2015 5.934.450.980 42.81%
2016 4.114.251.370 -44.24%
2017 4.978.132.650 17.35%
2018 5.923.106.940 15.95%
2019 15.073.380.670 60.7%
2020 15.968.005.690 5.6%
2021 19.977.754.860 20.07%
2022 26.625.933.670 24.97%
2023 28.329.350.750 6.01%

InBody Co.,Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
12717.05
Net Income per Share
2497
Price to Earning Ratio
11.51x
Price To Sales Ratio
2.26x
POCF Ratio
9.08
PFCF Ratio
10.64
Price to Book Ratio
1.63
EV to Sales
2.14
EV Over EBITDA
8.04
EV to Operating CashFlow
8.58
EV to FreeCashFlow
10.04
Earnings Yield
0.09
FreeCashFlow Yield
0.09
Market Cap
374,52 Bil.
Enterprise Value
353,71 Bil.
Graham Number
31449.68
Graham NetNet
7237.32

Income Statement Metrics

Net Income per Share
2497
Income Quality
1.27
ROE
0.15
Return On Assets
0.13
Return On Capital Employed
0.15
Net Income per EBT
0.86
EBT Per Ebit
1.11
Ebit per Revenue
0.22
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.75
Operating Profit Margin
0.22
Pretax Profit Margin
0.25
Net Profit Margin
0.22

Dividends

Dividend Yield
0.01
Dividend Yield %
1.04
Payout Ratio
0.12
Dividend Per Share
300

Operating Metrics

Operating Cashflow per Share
3166.3
Free CashFlow per Share
2703.22
Capex to Operating CashFlow
-0.15
Capex to Revenue
-0.04
Capex to Depreciation
-1.08
Return on Invested Capital
0.13
Return on Tangible Assets
0.13
Days Sales Outstanding
34.7
Days Payables Outstanding
16.71
Days of Inventory on Hand
268.62
Receivables Turnover
10.52
Payables Turnover
21.85
Inventory Turnover
1.36
Capex per Share
-463.08

Balance Sheet

Cash per Share
7.391,05
Book Value per Share
17.604,80
Tangible Book Value per Share
17593.47
Shareholders Equity per Share
17604.8
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.47
Current Ratio
7.13
Tangible Asset Value
229,19 Bil.
Net Current Asset Value
119,28 Bil.
Invested Capital
0
Working Capital
126,90 Bil.
Intangibles to Total Assets
0.01
Average Receivables
17,37 Bil.
Average Payables
1,83 Bil.
Average Inventory
28993603160
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

InBody Co.,Ltd Dividends
Year Dividends Growth
2001 50
2002 100 50%
2003 91 -11.11%
2004 50 -80%
2007 50 0%
2008 80 37.5%
2009 80 0%
2010 40 -100%
2011 40 0%
2012 40 0%
2013 40 0%
2014 60 33.33%
2015 80 25%
2016 100 20%
2022 300 66.67%

InBody Co.,Ltd Profile

About InBody Co.,Ltd

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

CEO
Dr. Ki-Chul Cha
Employee
266
Address
InBody Building
Seoul, 06106

InBody Co.,Ltd Executives & BODs

InBody Co.,Ltd Executives & BODs
# Name Age
1 Dr. Ki-Chul Cha
Chief Executive Officer
70
2 Yoon-Sun Shin
Managing Director
70
3 Ju-Sik Shin
Executive Officer
70

InBody Co.,Ltd Competitors

Vieworks Co., Ltd. Logo
Vieworks Co., Ltd.

100120.KQ

(0.0)
Osstem Implant Co., Ltd. Logo
Osstem Implant Co., Ltd.

048260.KQ

(0.0)
Seegene, Inc. Logo
Seegene, Inc.

096530.KQ

(0.0)
Medy-Tox Inc. Logo
Medy-Tox Inc.

086900.KQ

(0.0)